drugset / Trial / NCT04226950
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Objectives: To compare the efficacy and safety in childhood and adolescent patients (\<20 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study Design: A prospective, open-label, nonrandomized, single-center clinical trial
Timeline
- Start
- 2020-01-10
- Primary completion
- 2024-10-20
- Completion
- 2024-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 135 ug | — |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 180 ug | — |
| Comparator | Recombinant Interferon Alpha | Protein / enzyme biologic | 300 unknown | — |